Logo image of IVA

INVENTIVA SA - ADR (IVA) Stock Fundamental Analysis

NASDAQ:IVA - Nasdaq - US46124U1079 - ADR - Currency: USD

3.72  +0.16 (+4.49%)

Fundamental Rating

1

IVA gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. Both the profitability and financial health of IVA have multiple concerns. IVA is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year IVA has reported negative net income.
In the past year IVA has reported a negative cash flow from operations.
In the past 5 years IVA always reported negative net income.
IVA had a negative operating cash flow in each of the past 5 years.
IVA Yearly Net Income VS EBIT VS OCF VS FCFIVA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -50M -100M -150M

1.2 Ratios

The Return On Assets of IVA (-264.26%) is worse than 92.78% of its industry peers.
Industry RankSector Rank
ROA -264.26%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IVA Yearly ROA, ROE, ROICIVA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 -400

1.3 Margins

IVA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IVA Yearly Profit, Operating, Gross MarginsIVA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -2K -4K -6K -8K

More info and screens

0

2. Health

2.1 Basic Checks

IVA does not have a ROIC to compare to the WACC, probably because it is not profitable.
IVA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
IVA Yearly Shares OutstandingIVA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M 40M
IVA Yearly Total Debt VS Total AssetsIVA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

IVA has an Altman-Z score of -17.74. This is a bad value and indicates that IVA is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of IVA (-17.74) is worse than 83.98% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -17.74
ROIC/WACCN/A
WACC7.67%
IVA Yearly LT Debt VS Equity VS FCFIVA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 0.59 indicates that IVA may have some problems paying its short term obligations.
The Current ratio of IVA (0.59) is worse than 92.25% of its industry peers.
IVA has a Quick Ratio of 0.59. This is a bad value and indicates that IVA is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.59, IVA is not doing good in the industry: 92.08% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.59
Quick Ratio 0.59
IVA Yearly Current Assets VS Current LiabilitesIVA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

5

3. Growth

3.1 Past

The earnings per share for IVA have decreased strongly by -20.47% in the last year.
The Revenue for IVA has decreased by -47.37% in the past year. This is quite bad
IVA shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.62% yearly.
EPS 1Y (TTM)-20.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.47%
Revenue 1Y (TTM)-47.37%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%-41.21%

3.2 Future

IVA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.05% yearly.
The Revenue is expected to grow by 107.72% on average over the next years. This is a very strong growth
EPS Next Y56.03%
EPS Next 2Y25.06%
EPS Next 3Y16.7%
EPS Next 5Y20.05%
Revenue Next Year150.88%
Revenue Next 2Y91.87%
Revenue Next 3Y99.89%
Revenue Next 5Y107.72%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IVA Yearly Revenue VS EstimatesIVA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 200M 400M 600M 800M 1B
IVA Yearly EPS VS EstimatesIVA Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for IVA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IVA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IVA Price Earnings VS Forward Price EarningsIVA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IVA Per share dataIVA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3 -4

4.3 Compensation for Growth

IVA's earnings are expected to grow with 16.70% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.06%
EPS Next 3Y16.7%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IVA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INVENTIVA SA - ADR

NASDAQ:IVA (4/22/2025, 1:52:00 PM)

3.72

+0.16 (+4.49%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-26 2025-03-26/amc
Earnings (Next)07-29 2025-07-29
Inst Owners44.45%
Inst Owner Change0.2%
Ins Owners9.93%
Ins Owner ChangeN/A
Market Cap194.78M
Analysts86.67
Price Target10.17 (173.39%)
Short Float %0.86%
Short Ratio35.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.64%
PT rev (3m)-16.67%
EPS NQ rev (1m)-30%
EPS NQ rev (3m)-30%
EPS NY rev (1m)8.8%
EPS NY rev (3m)14.94%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-32.11%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 10.98
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.32
EYN/A
EPS(NY)-1.45
Fwd EYN/A
FCF(TTM)-1.85
FCFYN/A
OCF(TTM)-1.84
OCFYN/A
SpS0.34
BVpS-1.72
TBVpS-1.73
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -264.26%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.4
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.93%
Cap/Sales 3.62%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.59
Quick Ratio 0.59
Altman-Z -17.74
F-Score3
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-20.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-76.47%
EPS Next Y56.03%
EPS Next 2Y25.06%
EPS Next 3Y16.7%
EPS Next 5Y20.05%
Revenue 1Y (TTM)-47.37%
Revenue growth 3Y29.92%
Revenue growth 5Y5.62%
Sales Q2Q%-41.21%
Revenue Next Year150.88%
Revenue Next 2Y91.87%
Revenue Next 3Y99.89%
Revenue Next 5Y107.72%
EBIT growth 1Y10.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year29.98%
EBIT Next 3Y11.13%
EBIT Next 5Y21.64%
FCF growth 1Y-32.38%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.51%
OCF growth 3YN/A
OCF growth 5YN/A